vor 6 Jahren

Berlin to go, english edition 2/2015

  • Text
  • Berlin
  • Healthcare
  • Innovative
  • Scientific
  • Pharmaceutical
  • Germany


POINT OF VIEW Three questions to … District Mayor Norbert Kopp Mr Kopp, what distinguishes Steglitz-Zehlendorf from other districts? From an economic perspective I would describe the district of Steglitz-Zehlendorf as a centre for life sciences. With 19 clinics, 29 institutes and over 40 manufacturing and development companies in this sector, we are very well positioned here. The Free University, as one of eleven German universities with the University of Excellence status, complements this portfolio. What would you recommend to those who are visiting Steglitz-Zehlendorf for the first time? Where do I start? As a UNESCO World Heritage Site, the Klein-Glienicke Palace Park with its peacock island is well worth a visit, as are the district‘s unique museums such as the Liebermann Villa, the Brücke Museum and the Allied Museum. For fans of architecture, the Philology Library at the Free University of Berlin – designed by the renowned architect Norman Foster – is an absolute must. And for those who love to shop, I can only recommend the 2.1 km Steglitzer Schloßstraße, which boasts the most modern shopping centre in Berlin. In short: The district has something of interest for everyone! What would you like to change about your district? Unfortunately many spin-offs and startups from the Free University and the institutes established here find no space in the district in which to develop their young companies in close proximity to the university. We therefore lose many companies with a scientific orientation to other locations. Bearing in mind the upcoming Technology & Start-Up Centre in Dahlem‘s Fabeckstraße, this is thankfully set to change. Thanks for talking to us. Interview Gabriele Schulte-Kemper Business consultant for Steglitz-Zehlendorf MARC PAPPERT Project manager – Business services Berlin Partner for Business and Technology Fasanenstraße 85 / 10623 Berlin Tel + 49 30-46302-393 / Mobile +49 172 3998-224 Did you know … … that the first electric tram in the world was put into operation in Berlin-Lichterfelde in 1881? … that the Gutshaus Steglitz is one of the last buildings in the Early Prussian Classicism style? … that the district is home to numerous traditional and family-run companies, which can look back on a lengthy history, such as Autohaus Max Saparautzki (founded in 1923), Bernhard Halle Nachfolger GmbH (1911), Karl Dieringer (1903), BOGEN Electronic (1952), Knick (1945), KNAUER (1962) and Schröder Galvanik (1919)? … that today‘s Titania Cineplex in Steglitz held the first film festival after the Second World War? … that Zehlendorf is a popular shoot ing location for film-makers, and was used for example in the production of “The Reader” / Rathaus Zehlendorf, “James Bond 007 – Octopussy”/Hüttenweg, access to AVUS/or “Didi – Der Doppelgänger”/urban railway station at Mexikoplatz? Fotos: Porträt Norbert Kopp: Bezirksamt Steglitz-Zehlendorf; Porträt Marc Pappert: Berlin Partner/Fotostudio-Charlottenburg; Gutshaus Steglitz: Manfred Brückels –; Kino: 30 BERLIN TO GO

The founders: Dr. Wolf-Hagen Schunck, Dr. med. Robert Fischer, Dr. Karen Uhlmann and Dr. Dominik N. Müller START-UP INNOVATIVE TREATMENTS The Berlin start-up OMEICOS Therapeutics has successfully developed a new active pharmaceutical ingredient against atrial fibrillation Atrial fibrillation is the most common form of human cardiac arrhythmia. A growing number of patients with atrial fibrillation are faced with often limited medication-based treatment options. This situation could be remedied by a new treatment approach, which is being developed by OMEICOS Therapeutics. The Berlin start-up company, founded in 2013, has been successfully working for a number of years on a new active ingredient for minimising atrial fibrillation. This is based on research, in which a metabolic product of omega-3 fatty acids was identified as having a stabilising effect on the rhythm of the heart. Because attempts at effectively utilising the omega-3 fatty acids in treatments were previously not particularly successful, these were specifically produced as synthetic molecules with an identical structure. The preclinical data to date has shown that the synthetic active ingredient from OMEICOS is significantly more effective and stable than omega-3 fatty acids and their metabolic products, and that it is therefore better suited for use as a therapeutic agent. In contrast to conventional medi cations, the OMEICOS active pharmaceutical ingredient activates a natural, heart-protecting effect mechanism that also stabilises the rhythm of the heart. The aim of OMEICOS is to professionally develop the therapeutic approach with the active ingredient to the point of clinical use, and to make the medication available for heart patients. The management team of the innovative start-up consists of Dr. Robert Fischer, scientific director, and Dr. Karen Uhlmann, who brings with her many years of experi ence in the transfer of technology. photos: BBB Managment GmbH Omeicos in an interview How would you describe the innovative aspect of your treatment approach in simple words? Dr. Karen Uhlmann: Previous treatments tended to deal only with the symptoms, they attempt to fight against the rhythm disturbance through electrical influence. With the new active mechanism, we want to tackle the cause of atrial fibrillation instead. Dr. Robert Fischer: In contrast to today‘s treatments, which have numerous side-effects, we also anticipate better tolerability and therefore less side-effects in the long-term treatment of the disease. What support are you experiencing in Buch as a start-up company? Dr. Karen Uhlmann: Without the support from the Max Delbrück Center for Molecular Medicine (MDC) before founding our company, and the ongoing cooperation with the labora tories on the Buch campus, our work would have been almost impossible. Excellent cooperation with the campus management in particular was a great help. Their good understanding of the needs of a start-up company has made the Buch campus the ideal location for our company. What are your plans for the future? Dr. Robert Fischer: We are currently concentrating on further developing the active ingredient against atrial fibrillation for clinical trialling. Additionally, we are working on being able to treat further cardiovascular or chronic inflammatory diseases in the future with an active ingredient based on the OMEICOS technology platform. Thank you for talking to us. Interview Anke Templiner BERLIN TO GO 31

Publications in English

Publikationen auf deutsch